glp 1 agonist risks Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons | Dermatology and Therapy The expanding role of GLP-1

As of this review, only one large randomized clinical trial of semaglutide in youth has been completed, with a follow-up duration of 68 weeks [54]

In summary, the intricate interplay of metabolic abnormalities, inflammatory responses, and hormonal influences in obesity and diabetes underscores their significant impact on cancer risk and mortality

The same finding had been reported by a prior larger meta-analysis (6,914 patients with overweight or obesity and T2DM) over 8 studies 184,185,189,190,191,192,193,194 , but only when the largest study that also included non-diabetic participants 193 was excluded in a sensitivity analysis 195

Like tirzepatide , the active ingredient in Lillys Mounjaro and Zepbound , and semaglutide , the active ingredient in Wegovy and Ozempic from Novo Nordisk, retatrutide mimics the appetite- and blood-sugar-reducing effects of a hormone called glucagon-like peptide 1, or GLP-1

2nd & Conti, R